The rationale for targeting the CCL17/CCL22/CCR4 chemokine axis was based on the contribution of this signaling axis to ATLL progression and tissue infiltration (see previous Section 2.2.3). This evidence concerns the gene CCL22 and adult T-cell leukemia/lymphoma.